MedTrace Logo

COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2

NCT04354766 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-06-18

No results posted yet for this study

Summary

Rationale : The emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) threatens public health. To date, there are no effective drug option to prevent the infection, nor therapeutics for controlling the deadly COVID-19. However, the majority of patients infected with SARS-Cov-2 eliminate the virus by mounting a protective antiviral immune response, associated in particular with the production of neutralizing antibodies. Neutralizing antibodies could be of particular interest for therapeutic purposes, but also for preventive applications, to protect people who have never been in contact with the virus, or immunocompromised patients.

The objectives of this study are :

* To generate human monoclonal antibodies neutralizing SARS-Cov-2 from immortalized B cells of convalescent patients.
* To compare the serological profiles between convalescent patients that develop mild or uncomplicated illness and convalescent patients that develop a more severe disease, that required hospitalization and oxygen support.
* To compare for each patient the neutralizing efficiency of plasma to the neutralizing capacities of the monoclonal antibodies generated with immortalized B cells.

Conditions

Interventions

OTHER

Blood sample

This study will require a blood sample (4 ACD tubes, 20 ml) at one time.

Sponsors & Collaborators

  • Eurobio Scientific

    collaborator UNKNOWN

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Frédéric COUTANT, MD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-29
Primary Completion
2020-05-18
Completion
2020-05-18

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04354766 on ClinicalTrials.gov